GSK (LON:GSK) Price Target Cut to GBX 1,600 by Analysts at Berenberg Bank

GSK (LON:GSK) had its target price reduced by equities research analysts at Berenberg Bank from GBX 1,820 ($23.04) to GBX 1,600 ($20.25) in a research note issued on Friday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price target suggests a potential upside of 19.27% from the company’s current price.

A number of other analysts have also commented on GSK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($23.41) price objective on shares of GSK in a research report on Tuesday, September 3rd. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.86).

GSK Stock Up 0.5 %

Shares of GSK traded up GBX 6.50 ($0.08) during midday trading on Friday, hitting GBX 1,341.50 ($16.98). The stock had a trading volume of 4,419,101 shares, compared to its average volume of 10,052,011. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a market cap of £54.73 billion, a price-to-earnings ratio of 1,187.17, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a twelve month low of GBX 1,282.50 ($16.23) and a twelve month high of GBX 1,823.50 ($23.08). The company has a 50 day simple moving average of GBX 1,437.76 and a two-hundred day simple moving average of GBX 1,550.44.

Insider Transactions at GSK

In other news, insider Jonathan Symonds acquired 7,150 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of GBX 1,394 ($17.64) per share, with a total value of £99,671 ($126,149.85). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average price of GBX 2,051 ($25.96) per share, with a total value of £9,147.46 ($11,577.60). Over the last ninety days, insiders have acquired 7,604 shares of company stock valued at $10,893,038. 1.61% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.